Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.41 |
| ▸ | STK3 | Q13188 | 2/20 | 0.35 |
| ▸ | STK4 | Q13043 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | PRKCG | P05129 | 1/20 | 0.34 |
| ▸ | INSR | P06213 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017049 | 0.92 | PIK3CD (0.46) | PIK3CDSLC40A1PIK3R2 | |
| SCHEMBL2014973 | 0.88 | PIK3CD (0.45) | PIK3CDSLC40A1PIK3CGPIK3R2SOS1 | |
| SCHEMBL2017133 | 0.85 | PIK3CD (0.48) | PIK3CDDYRK1APIK3R2 | |
| SCHEMBL2018067 | 0.84 | PIK3CD (0.44) | PIK3CDLRRK2SLC40A1IRAK4PIK3R2 | |
| SCHEMBL2013199 | 0.84 | PIK3CD (0.44) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL12470100 | 0.84 | PIK3CD (0.45) | PIK3CDPIK3R2 | |
| SCHEMBL2012980 | 0.83 | PIK3CD (0.43) | PIK3CDLRRK2SLC40A1 | |
| SCHEMBL2015748 | 0.83 | PIK3CD (0.43) | PIK3CDLRRK2SLC40A1 | |
| SCHEMBL2014219 | 0.83 | PIK3CD (0.45) | PIK3CDLRRK2CDC7PIK3R2KRAS | |
| SCHEMBL2012187 | 0.83 | PIK3CD (0.43) | PIK3CDSLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | claimed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | claimed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | claimed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | PIK3CD 13/4885STK3 453/4885STK4 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.